Oliver Luxxe Assets LLC Invests $1.47 Million in ICU Medical, Inc. $ICUI

Key Points

• Oliver Luxxe Assets LLC invested $1.47 million in ICU Medical, purchasing 10,558 shares, highlighting institutional interest in the company's stock.
• ICU Medical's recent quarterly earnings report showed an EPS of $2.10, exceeding analysts' expectations, despite an 8% decline in year-over-year revenue.
• Several analysts have adjusted their ratings and price targets for ICU Medical, with the average target now at $179.00 following a mix of buy, hold, and overweight ratings.

Oliver Luxxe Assets LLC purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,558 shares of the medical instruments supplier's stock, valued at approximately $1,466,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. grew its holdings in shares of ICU Medical by 18.5% during the first quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier's stock valued at $96,326,000 after purchasing an additional 108,493 shares during the last quarter. Martingale Asset Management L P increased its stake in shares of ICU Medical by 28.3% during the first quarter. Martingale Asset Management L P now owns 21,561 shares of the medical instruments supplier's stock valued at $2,994,000 after acquiring an additional 4,761 shares during the period. Versor Investments LP boosted its stake in ICU Medical by 26.8% during the first quarter. Versor Investments LP now owns 6,604 shares of the medical instruments supplier's stock valued at $917,000 after buying an additional 1,397 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of ICU Medical by 7.5% in the 1st quarter. Raymond James Financial Inc. now owns 69,297 shares of the medical instruments supplier's stock worth $9,623,000 after purchasing an additional 4,833 shares during the last quarter. Finally, Public Sector Pension Investment Board lifted its position in shares of ICU Medical by 27.3% during the 1st quarter. Public Sector Pension Investment Board now owns 77,627 shares of the medical instruments supplier's stock valued at $10,779,000 after acquiring an additional 16,627 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Trading Up 0.3%

ICU Medical stock traded up $0.42 during midday trading on Thursday, hitting $127.04. 219,661 shares of the stock were exchanged, compared to its average volume of 268,154. The company has a fifty day simple moving average of $126.90 and a two-hundred day simple moving average of $136.37. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $3.14 billion, a PE ratio of -83.58 and a beta of 0.88. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. During the same period in the prior year, the business earned $1.56 EPS. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ICUI has been the subject of a number of research analyst reports. Piper Sandler initiated coverage on ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 target price for the company. Raymond James Financial decreased their price target on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a report on Friday, August 8th. Finally, Wall Street Zen downgraded shares of ICU Medical from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $179.00.

Insider Buying and Selling

In other ICU Medical news, Director David C. Greenberg acquired 1,200 shares of the business's stock in a transaction dated Wednesday, August 27th. The shares were acquired at an average price of $126.42 per share, with a total value of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Vivek Jain bought 21,929 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares of the company's stock, valued at $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by company insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.